Status:
COMPLETED
Adherence With Continuous-dose Oral Contraceptive: Evaluation of Self-Selection and Use
Lead Sponsor:
HRA Pharma
Conditions:
Contraception
Eligibility:
FEMALE
11+ years
Phase:
PHASE3
Brief Summary
This study is designed to assess whether consumers select and use norgestrel 0.075 mg, a progestin only pill for contraception, in a manner consistent with the OTC package directions in an Over-the-Co...
Detailed Description
Subjects will be primarily recruited via passive recruiting methods, such as in-store posters, direct mail postcards, and digital space advertising. Respondents to advertisements will either call the...
Eligibility Criteria
Inclusion
- Women who are willing to purchase (in the pharmacies) or be provided (in the clinics, for women younger than 18 years old) oral contraception for their own use for the purposes of the study
Exclusion
- Cannot read, speak and understand English
- Cannot see well enough to read information on the label
Key Trial Info
Start Date :
September 6 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 5 2021
Estimated Enrollment :
962 Patients enrolled
Trial Details
Trial ID
NCT04112095
Start Date
September 6 2019
End Date
August 5 2021
Last Update
May 20 2022
Active Locations (38)
Enter a location and click search to find clinical trials sorted by distance.
1
HRA Pharma Investigational site 1012
Birmingham, Alabama, United States, 35215
2
HRA Pharma Investigational Site 1008
Homewood, Alabama, United States, 35209
3
HRA Pharma Investigational Site 1038
Mesa, Arizona, United States, 85203
4
HRA Pharma Investigational Site 1032
Phoenix, Arizona, United States, 85021